biostudies-literatureUnknown32(3)Melero IF. Hoffmann-La Roche Ltd<h4>Purpose</h4>Cergutuzumab amunaleukin (CA) is an immunocytokine comprising a variant form of interleukin 2 (IL2) [constructed to avoid CD25 binding and regulatory T-cell (Treg) stimulation] fused to a carcinoembryonic antigen (CEA)-targeted antibody. This phase Ib open-label, multicenter dose-escalation and -expansion study (NCT02350673) evaluated the safety, activity, pharmacokinetics, and pharmacodynamics of CA plus atezolizumab in patients with advanced/metastatic CEA-positive solid tumors.<h4>Patients and methods</h4>Patients received escalating doses of CA (6-20/25 mg) with fixed dosages of atezolizumab (840 mg) every 2 weeks or escalating dosages of CA weekly (10-15/20 mg) with fixed dosages of atezolizumab (1,200 mg) every 3 weeks. Primary objectives include maximum tolerated dosClinical cancer research : an official journal of the American Association for Cancer Research528-539https://www.ebi.ac.uk/biostudies/studies/S-EPMC12869162biostudies-literatureCergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.PMC12869162Hafez NTeichgraber VLassen UO'Reilly EMEvers SMelero IMartinez Quetglas IRobbrecht DGJBoetsch CPeters SAdessi CSteeghs NLeighl NDejardin DRossmann ECharo JTabernero JEefsen RLBabitzki GCervantes ARizvi NAHabigt CAndersson EDuarte JCalvo EfalseCergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.<h4>Purpose</h4>Cergutuzumab amunaleukin (CA) is an immunocytokine comprising a variant form of interleukin 2 (IL2) [constructed to avoid CD25 binding and regulatory T-cell (Treg) stimulation] fused to a carcinoembryonic antigen (CEA)-targeted antibody. This phase Ib open-label, multicenter dose-escalation and -expansion study (NCT02350673) evaluated the safety, activity, pharmacokinetics, and pharmacodynamics of CA plus atezolizumab in patients with advanced/metastatic CEA-positive solid tumors.<h4>Patients and methods</h4>Patients received escalating doses of CA (6-20/25 mg) with fixed dosages of atezolizumab (840 mg) every 2 weeks or escalating dosages of CA weekly (10-15/20 mg) with fixed dosages of atezolizumab (1,200 mg) every 3 weeks. Primary objectives include maximum tolerated dos2026-01-01T00:00:00Z2026 Feb2026-07-15T06:07:50.3Z2026-07-01T03:07:45.314ZS-EPMC128691624125257410.1158/1078-0432.CCR-25-2440